ROSEN, A LEADING LAW FIRM, Encourages Mullen Automotive, Inc. f/k/a Net Element, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MULN, NETE
SO WHAT: If you purchased Mullen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Mullen class action, go to https://rosenlegal.com/submit-form/?case_id=35234 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Mullen had no intent of implementing a reverse stock split when in-fact the Chief Executive Officer David Michery ('CEO' or 'Michery'), and Mullen believed one was imminent and necessary; (2) Mullen overstates its deals with business partners, including Rapid Response Defense Systems ('RRDS') and Mullen Advanced Energy Operations, LLC ('MAEO'); (3) Mullen overstates its battery technology capabilities and partnerships (i.e., Lawrence Hardge related allegations); (4) Mullen misled the investing public about its reverse splits; (5) Mullen and Michery knew or should have known about Lawrence Hardge's previous convictions for financial crimes and moral turpitude and disclosed this information to investors; (6) Mullen failed to disclose material information about its financing agreements; and (7) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Mullen class action, go to https://rosenlegal.com/submit-form/?case_id=35234 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
24 minutes ago
- The Hill
Apple faces steep tariffs
{beacon} Technology Technology The Big Story Apple anticipates $1.1B price tag from tariffs next quarter Apple expects to face $1.1 billion in tariff-related costs next quarter on top of $800 million from the prior three months. © Alberto Pezzali, Associated Press The iPhone-maker, which has been hit particularly hard by President Trump's tariff push, still reported strong quarterly earnings, posting $94 billion in revenue and $23.4 billion in net income for the stretch between April and June. Apple sold $44.5 billion worth of iPhones last quarter, up 13 percent from the same three-month period last year, at least part of which the company attributed to consumers trying to get ahead of tariffs. 'We would estimate the pull-forward of demand into April specifically to be about one point of the 10 points in terms of people buying because of discussions about tariffs,' Apple CEO Tim Cook said Thursday, referencing the 10 percent uptick in sales last quarter. The company has found itself in a tricky position on tariffs in Trump's second term. It has long manufactured most of its products in China but has increasingly sought to diversify its supply chain by moving some production to India and Vietnam. This has been less than beneficial given the president's wide-ranging approach to tariffs this time around. Trump initially hit all three countries with hefty 'reciprocal' tariffs before putting most on pause. Tariffs on Chinese goods remained in place, as Washington and Beijing went tit for tat on import taxes, raising levies on one another to 145 percent and 125 percent, respectively. The two sides eventually struck an agreement to lower their tariffs to 30 percent and 10 percent, a truce they agreed to extend Tuesday for an additional 90 days. In the meantime, Apple has shifted more production to India, prompting the country to overtake China as the leading exporter of smartphones to the U.S. last quarter. Check out the full report at Welcome to The Hill's Technology newsletter, I'm Julia Shapero — tracking the latest moves from Capitol Hill to Silicon Valley. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the tech sector now and in the future: Tesla found partly liable for fatal autopilot crash A federal jury on Friday found Elon Musk's Tesla partially liable for a fatal 2019 crash involving the electric vehicle maker's autopilot system. The Miami jury determined Tesla was 33 percent responsible for the crash and ordered the company to pay several million dollars in damages. The family of Naibel Benavides sued the EV maker over the crash that resulted in the 22-year-old's death, alleging the company's … Full Story Senate Democrats call for probe into DOJ settlement over HPE-Juniper merger Several Senate Democrats are calling for an investigation into the Department of Justice's (DOJ) decision to settle a lawsuit blocking Hewlett Packard Enterprise's (HPE) $14 billion acquisition of Juniper Networks. Democratic Sens. Richard Blumenthal (Conn.), Cory Booker (N.J.), Elizabeth Warren (Mass.) and Amy Klobuchar (Minn.) raised concerns to the DOJ inspector general Friday about the circumstances surrounding the … Full Story Astronauts launch to the space station after sidelined by Boeing's troubled Starliner CAPE CANAVERAL, Fla. (AP) — Astronauts sidelined for the past year by Boeing's Starliner trouble blasted off to the International Space Station on Friday, getting a lift from SpaceX. Full Story The Refresh News we've flagged from the intersection of tech and other topics: Palantir gets $10 billion contract from U.S. Army (Washington Post) OpenAI raises $8.3 billion in latest funding round (New York Times) Crypto Corner SEC launches Project Crypto © AP Photo/Andrew Harnik Securities and Exchange Commission (SEC) Chair Paul Atkins is launching a new initiative to update securities rules and regulations to "enable America's financial markets to move on-chain." Atkins announced his plans for Project Crypto on Thursday, directing agency staff to develop proposals for implementing recommendations from the Trump administration's recent crypto report. The 166-page report from the president's digital assets working group offered detailed guidance to Congress and federal regulators on everything from crypto oversight to taxation to banking rules. It notably urged both the SEC and the Commodity Futures Trading Commission (CFTC) to 'use their existing authorities to immediately enable the trading of digital assets at the federal level.' Atkins said Thursday he is directing SEC staff to draft rules on crypto asset distributions, custody and trading, in addition to considering authorities to "make sure that archaic rules and regulations do not smother innovation and entrepreneurship in America." For instance, the SEC chair said he has tasked his staff with developing guidelines to determine when a crypto asset is a security or subject to an investment contract (which also falls under the agency's purview). He also called for fit-for-purpose disclosures, exemptions and safe harbors for crypto transactions that are covered by securities laws. Crypto Corner is a daily feature focused on digital currency and its outlook in Washington. In Other News Branch out with other reads on The Hill: Google loses appeal in antitrust battle with Fortnite maker SAN FRANCISCO (AP) — A federal appeals court has upheld a jury verdict condemning Google's Android app store as an illegal monopoly, clearing the way for a federal judge to enforce a potentially disruptive shakeup that's designed to give consumers more choices. Full Story You're all caught up. See you next week!
Yahoo
an hour ago
- Yahoo
Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run.
Key Points Palantir Technologies now ranks in the top 25 of the most valuable companies in the world. Its Artificial Intelligence Platform (AIP) is wildly popular for commercial and government clients. 10 stocks we like better than Palantir Technologies › There are probably few investors out there who are more satisfied than those who bought Palantir Technologies (NASDAQ: PLTR) stock early in its run. The artificial intelligence (AI) company is blowing other stocks out of the water these days, with its stock up 478% in the last year and more than doubling in 2025. Palantir is now one of the world's top 25 most valuable companies, ahead of such blue chip names as Procter & Gamble and Bank of America. Palantir's run is fueled by the adaptation of its Artificial Intelligence Platform (AIP) by government and commercial clients, fueling dramatic growth in both revenue and earnings. And with Palantir set to report second-quarter earnings on Aug. 4, there are plenty of reasons to believe that this run is far from over. How Palantir is making money Palantir already had two AI-powered platforms. Its Gotham platform is prized by governments and defense agencies to gather information from multiple sources, identify targets, and make real-time assessments to provide insights about battlefield situations. Palantir is recognized for helping the U.S. military track down 9/11 mastermind Osama bin Laden in 2011. Then you have the Foundry platform used by Palantir's commercial clients. Foundry helps clients manage supply chains and inventory, automate workflows, and optimize operations. The AIP platform made both of these powerful tools better and easier to use because AIP allows users to make detailed queries, and then it generates responses using generative AI. And the results are evident in the massive gains the company is seeing: Since rolling out AIP in April 2023, Palantir's revenues have gone through the roof. Year Revenue Profit (Loss) Earnings per Share 2021 $1.54 billion ($520.3 million) ($0.27) 2022 $1.90 billion ($161.2 million) ($0.18) 2023 $2.22 billion $217.3 million $0.10 2024 $2.86 billion $467.9 million $0.21 2025 (projected) $3.90 billion Image source: Palantir Technologies. In the first quarter of 2025, the company reported revenue of $884 million, up 39% from a year ago. U.S. commercial revenue jumped 71% from a year ago to $255 million, and U.S. government revenue was up 45% from a year ago to $373 million. The stock is by far outperforming the biggest companies on the planet, as well as the S&P 500 and the Nasdaq Composite. What can we expect from Palantir next? The second quarter is expected to be another blowout quarter. The company is continuing to reel in work, including contracts with the Navy to improve ship production and fleet readiness and a partnership with Accenture (NYSE: ACN) to develop AI solutions for federal agencies. On the commercial side, Palantir signed a deal with The Nuclear Company to develop and modernize nuclear power plants, as well as an agreement with The Joint Commission to use AI to manage accreditation and certification standards at hospitals and healthcare organizations. Palantir issued guidance for second-quarter revenue of $934 million to $938 million -- the midpoint of that would be a 38% increase from Q2 2024. Its full-year guidance is now in a range from $3.89 billion to $3.902 billion. The main argument for investing in Palantir today, of course, is the valuation. With a trailing price-to-earnings ratio (P/E) of 682 and a forward P/E of 269, Palantir is ungodly expensive. But that's not a deal-breaker for me. I keep remembering that Amazon had a P/E of more than 1,000 back in 2013 before people realized how important cloud computing and its Amazon Web Services platform would be. I think Palantir is like Amazon -- people are just starting to appreciate that Palantir is a transformative company that is changing the world and how businesses and governments operate. And when it reports earnings on Aug. 4, I think you're going to continue to see the stock soar. How to invest in Palantir I would never recommend that someone overinvest in a stock or put their entire nest egg into Palantir. But I do think it's a company that should be part of a portfolio. If you are worried about the inherent volatility that comes with a stock that's growing as quickly as Palantir (and has such a crazy valuation), I recommend using a dollar-cost averaging strategy to establish your position over time. Just be sure never to be overextended on any one stock -- even one as compelling as Palantir. Should you buy stock in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Bank of America is an advertising partner of Motley Fool Money. Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Accenture Plc, Amazon, Apple, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run. was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact: Justine O'Malley Protara 646-817-2836 Source: Protara TherapeuticsSign in to access your portfolio
